Evgenii A. Luchinin

Evgenii A. Luchinin

Auto-generated profile, based on publicly available information

Evgenii A. Luchinin

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Актуальные проблемы медицины
Verified
Journal Article
Closed access
ARArtem V. Ruta
Artem V. Ruta
ELElena V. Luchinina
Elena V. Luchinina
TSTatyana V. Shelekhova
Tatyana V. Shelekhova
ELEvgeny A. Luchinin
Evgeny A. Luchinin
MZMarina R. Zaitseva
Marina R. Zaitseva
RBRoman A. Bontsevich
Roman A. Bontsevich

30 April 2022 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Verified
Journal Article
Open access
PDF file
MZM. V. Zhuravleva
M. V. Zhuravleva
GKG. V. Kukushkin
G. V. Kukushkin
ELE. V. Luchinina
E. V. Luchinina
TST. V. Shelekhova
T. V. Shelekhova
TKT. R. Kameneva
T. R. Kameneva
ELE. A. Luchinin
E. A. Luchinin
Анализ стоимости лечения адеметионином больных внутрипечёночным холестазом и неалкогольной жировой болезнью печени

29 March 2024 in South Russian Journal of Therapeutic Practice
Verified
Journal Article
Open access
PDF file
ARA. V. Ruta
A. V. Ruta
ELE. V. Luchinina
E. V. Luchinina
TST. V. Shelekhova
T. V. Shelekhova
ELE. A. Luchinin
E. A. Luchinin
MZM. R. Zaitseva
M. R. Zaitseva
The purpose of this review is to provide clinicians with information and a concise interpretation of the results of pharmacogenetic testing for the cytochrome P450 2C19 (CYP2C19) genotype when choosing a proton pump inhibitor (PPI) dosage. PPIs are widely used for the treatment and prevention of common gastrointestinal diseases, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, and other hypersecretory conditions. Most PPIs are metabolized predominantly by cytochrome P450 2C19 (CYP2C19) to form inactive metabolites, and the CYP2C19 genotype determines the action of PPIs, their efficacy and possible side effects. In clinical practice, a gastroenterologist or therapist is faced with problems of insufficient effectiveness or the development of adverse reactions when prescribing PPIs. Thus, consideration of CYP2C19 genotype appears to be necessary to determine the optimal PPI dosing regimen. The above served as a reason for generalizing in the presented review of literature data on the prescription of PPIs depending on the CYP2C19 genotype.

15 November 2022 in Problems of Social Hygiene, Public Health and History of Medicine
Verified
Journal Article
Open access
PDF file
AZAlena I. Zagrebneva
Alena I. Zagrebneva
ELE A Luchinin
E A Luchinin
ASA V Smirnova
A V Smirnova
VMV I Mitrofanova
V I Mitrofanova
MHM E Holownia-Voloskova
M E Holownia-Voloskova
The article is a comparative analysis of the quality of life indicators of patients with rheumatoid arthritis with similar indicators in the Moscow population. We conducted a survey of patients in the register of rheumatoid patients in Moscow using the EQ-5D-5L questionnaire and the EQ-VAS visual analog scale. The population of patients with rheumatoid arthritis, in accordance with the recommendations of EuroQoL, was divided into 6 age and sex groups. The responses of patients from each age and sex group were compared with similar groups of respondents in the Moscow population. Key differences in the quality of life of rheumatoid patients were identified in comparison with both the population norm in Moscow and similar foreign registries.

17 March 2026 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
TSTatyana V. Shelekhova
Tatyana V. Shelekhova
ARArtem V. Ruta
Artem V. Ruta
ELElena V. Luchinina
Elena V. Luchinina
RBRoman A. Bontsevich
Roman A. Bontsevich
MZMarina R. Zaitсeva
Marina R. Zaitсeva
ELEvgeny А. Luchinin
Evgeny А. Luchinin
Introduction: Losartan, a selective angiotensin II receptor type 1 antagonist, is transported across cell membrane mediated by P-glycoprotein, the product of the ABCB1 (also known as MDR1) gene. The level of expression of this transporter protein is characterized by significant individual variability, caused by genetic factors. Well-known polymorphisms C3435T and C1236T in the ABCB1 gene potentially could affect a functional activity of the P-glycoprotein, thus modulating the pharmacokinetic parameters and clinical efficacy of the substrates of this transporter, including losartan. Therefore, the aim of this research is to indicate the correlation between common SNPs C3435T and C1236T of the MDR1 gene and the efficacy of 6-week losartan monotherapy course in patients with a newly diagnosed arterial hypertension (AH). Materials and Methods: The study included 34 patients (70.6% women, mean age 48.3 ± 7.4 years). All participants were given losartan 100 mg/day for 6 weeks. Genotyping for C3435T and C1236T polymorphisms was made by using allele-specific PCR with electrophoretic detection. The efficacy of the therapy was evaluated by the reduction of systolic (SBP) and diastolic (DBP) blood pressure from the reference level. Results: Patients with CT or TT genotypes for the C3435T polymorphism showed a statistically meaningful, greater reduction in SBP (11.8% ± 9.7) compared to homozygous CC genotype (”wild” type; 6.7% ± 9.6; p=0.03). No significant differences were found in SBP reduction for the C1236T polymorphism (p=0.07). Changes in DBP did not correlate with either of the studied polymorphisms. Conclusions: The C3435T genetic polymorphism of the MDR1 gene is a potential predictor of the efficacy of losartan antihypertensive therapy. The carriers of the T allele (CT/TT genotypes) demonstrate more expressed hypotensive response, which may be caused by modulation of tissue distribution of the drug or its interaction with endogenous systems (ouabain) regulating blood pressure. The obtained data highlights the importance of a pharmacogenetic approach for personalizing AH treatment.

30 December 2020 in Health Care of the Russian Federation
Verified
Journal Article
Closed access
PDF file
ЕКЕкатерина Борисовна Корнилова
Екатерина Борисовна Корнилова
MHMalwina Ewa Hołownia-Voloskova
Malwina Ewa Hołownia-Voloskova
EAElena S. Ar’kOva
Elena S. Ar’kOva
DRDmitriy A. Roslik
Dmitriy A. Roslik
ELEvgenii A. Luchinin
Evgenii A. Luchinin
ЕАЕ. С. Арькова
Е. С. Арькова
Introduction. Such medical technology like a direct antiviral drugs for treatment for chronic hepatitis C (CHC) remains inaccessible due to high absolute cost for health care systems, lack of assessment in specific region of Russian Federation and correlation with results of used antiviral therapy options. The purpose of the study is to determine most cost-effective option of drug provision with direct antiviral drugs for the treatment of chronic hepatitis C. Material and methods. Based on the population of chronic hepatitis C adult patients receiving medications at expense of Moscow budget funds, was performed a pharmacoeconomic analysis of drug therapy with direct antiviral drugs. Results.The use of new pangenotypic direct antiviral drugs for the treatment of CHC in a clinically heterogeneous population of Russian adults with 1-6 genotypes of the hepatitis C virus is economically justified. Both alternative scenarios demonstrated an advantage over the baseline scenario in the form of financial savings of 66,028,192. 45 rubles and 83,647,819.27 rubles and an increase in the number of effectively treated patients by 197 and 287 people per year, respectively. Conclusion. An increase in the share of new direct antiviral drugs in drug supply programs will increase the efficiency of the use of financial resources and increase the availability of direct antiviral drugs, which may ultimately lead to the achievement of an epidemiological effect on a population scale.